Semaglutide Archives - Xtalks

Wednesday, August 12, 2026 | 11am EDT: Accelerate Cell Culture Media Development with Automated Cell Analysis

Novo Nordisk Canada Moves to Keep Ozempic Affordable for Some Uninsured Patients

Apotex Leads Race for Generic Ozempic with Tentative FDA Approval

Novo Nordisk and Hims & Hers Bury the Hatchet and Partner to Expand Access to Ozempic, Wegovy

Wegovy HD Receives FDA Approval as Fourth Product Under National Priority Voucher Program

Ozempic Lawsuits Continue With Second US Mass Litigation Involving GLP-1 Drugs and Vision Loss

December 19, 2025

Vimy Pharma to Launch Made-In-Canada Ozempic Generic

October 24, 2025

Top 3 Best-Selling Weight-Loss Drugs to Watch in 2025

September 10, 2025

Hims & Hers Pairs Up with Novo Nordisk to Offer Discounted Wegovy, After Previous Feud

CagriSema, Novo Nordisk’s Latest Obesity Drug Offering, Disappoints Investors with Trial Results

FDA Approves New Use for Ozempic to Reduce the Risks of Kidney Disease

January 29, 2025

Zepbound Versus Wegovy: Head-to-Head Trial Reveals Which Has the Weight Loss Edge

December 6, 2024

What Are the Top 10 Diabetes Medications? A Look at Recent Sales Trends

December 3, 2024

Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight

November 15, 2024

Novo Nordisk Takes Wegovy to MASH, Sharing Promising Data from First Part of Trial

November 5, 2024

GLP-1 Drugs Mounjaro, Zepbound, Wegovy Back in Stock After Extended Shortages

August 22, 2024

FDA Warns of Dosing Errors with Compounded Semaglutide Injectables

Next Page »